Dr. Chari on Using Selinexor in Multiple Myeloma Treatment

Ajai Chari, MD
Published: Friday, Sep 20, 2019



Ajai Chari, MD, associate professor, hematology and medical oncology, Mount Sinai Hospital, discusses the use of selinexor (Xpovio) in multiple myeloma treatment.

Selinexor was approved by the FDA due to data involving patients with multiple myeloma who were refractory to proteasome inhibitors, immunomodulatory agents, and a CD38-targeted monoclonal antibody, explains Chari. Historically, there has been no FDA-approved therapy for this patient population. The overall response rate (ORR) of selinexor was 26% with a median progression-free survival (PFS) of 3.5 months, response rates that are similar to the profiles of other approved drugs, including pomalidomide (Pomalyst), carfilzomib (Kyprolis), and daratumumab (Darzalex), when used as a single agent, says Chari.

Additionally, the adverse events due to toxicities for selinexor are manageable at Mount Sinai Hospital, according to Chari. Mount Sinai Hospital is aggressive with supportive care, showing efficacy results that are better than the overall study population with selinexor. Mount Sinai Hospital is working on a manuscript where the ORR is over 50% and the median PFS is over 5 months, demonstrating the importance of supportive care in this population, concludes Chari.

<<< 17th International Myeloma Workshop


Ajai Chari, MD, associate professor, hematology and medical oncology, Mount Sinai Hospital, discusses the use of selinexor (Xpovio) in multiple myeloma treatment.

Selinexor was approved by the FDA due to data involving patients with multiple myeloma who were refractory to proteasome inhibitors, immunomodulatory agents, and a CD38-targeted monoclonal antibody, explains Chari. Historically, there has been no FDA-approved therapy for this patient population. The overall response rate (ORR) of selinexor was 26% with a median progression-free survival (PFS) of 3.5 months, response rates that are similar to the profiles of other approved drugs, including pomalidomide (Pomalyst), carfilzomib (Kyprolis), and daratumumab (Darzalex), when used as a single agent, says Chari.

Additionally, the adverse events due to toxicities for selinexor are manageable at Mount Sinai Hospital, according to Chari. Mount Sinai Hospital is aggressive with supportive care, showing efficacy results that are better than the overall study population with selinexor. Mount Sinai Hospital is working on a manuscript where the ORR is over 50% and the median PFS is over 5 months, demonstrating the importance of supportive care in this population, concludes Chari.

<<< 17th International Myeloma Workshop



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x